Table of Contents
Trial overview
The clinical trial in the source data studied 18F-Fludarabine PET/MR imaging in people with newly diagnosed primary central nervous system lymphoma.[1] The purpose was to characterize the cerebral distribution of the tracer and its uptake in the tumor before any surgery, chemotherapy, or radiotherapy.[1]
Who was studied
The study included patients with newly diagnosed primary CNS lymphoma who had not yet received surgery, radiotherapy, or chemotherapy.[1] This means the trial focused on people at the start of their cancer care, before treatment could change the scan results.[1]
The condition under study was primary central nervous system lymphoma, a lymphoma that starts in the brain or spinal cord area.[1] The trial was designed as an interventional study, meaning researchers actively used the imaging procedure and then measured the results.[1]
What was measured
The main outcome was the standardized measurement of tumor uptake, also called standardized uptake value (SUV).[1] SUV is a number that shows how much tracer a tissue absorbs on imaging.[1]
Researchers compared SUV in tumor lesions with SUV in healthy tissue on PET images that were superimposed on MRI images.[1] This comparison helped show whether the tracer gathered more in the lymphoma than in normal brain tissue.[1]
Imaging method used
The study used PET/MR imaging, which combines positron emission tomography (PET) and magnetic resonance imaging (MRI).[1] PET shows where the tracer goes in the body, while MRI gives detailed pictures of the brain and nearby tissues.[1]
The trial also used gadoteric acid as an imaging drug listed in the intervention section.[1] The source data do not provide more detail about how it was used, so the main focus of the study remains the 18F-Fludarabine PET/MR scan.[1]
Trial status and size
The study was a Phase 1 trial and was completed.[1] It enrolled 16 participants, which is a small number typical of an early pilot study.[1]
Because this was a pilot study, the main goal was to learn whether the imaging approach could describe tumor uptake and brain distribution in this patient group.[1] The source data do not report treatment benefit, because the trial focused on imaging measurements rather than therapy.[1]
